NEW YORK (GenomeWeb News) — Thermo Fisher Scientific today said it has completed the sale of its Genevac business to Riverlake Equity Partners.
Thermo said Genevac brought in around $17 million in annual sales.
As GenomeWeb News reported last October, the Federal Trade Commission and the European Commission required that Fisher Scientific divest the Ipswich, UK-based company before it can merge with Thermo Electron.
The FTC and the EC required Thermo to sell the business by April 9.